BOSTON, Jan. 6, 2011 /PRNewswire/ — Solos Endoscopy, Inc. (Pink
SNDY) is pleased to announce that the Company looks towards
continued growth in 2011 through new product development, new
product sales and the completion of the requirements for its ISO
13485 quality management system (QMS) initiative, which is a major
step in obtaining the CE Mark and the permission to sell medical
devices in the European Union.
Early in 2010, Solos retained Expert Resource (ER) to provide
consulting services in support of the Company’s ISO 13485 quality
management system (QMS) initiative as well as obtaining the CE
Mark. Since this time, the Company has successfully completed Phase
One (of Four) requirements for the Company’s ISO 13485 quality
management system (QMS) initiative. In addition to this milestone,
Solos announced in March 2010 that the Company had secured the U.S.
Trademark registration (#3637510) for the protection of the
MammoView® name. Throughout 2010, the Company remained focused
on new product design and development announcing the design of a
new Polymer Dilator and separate Relay Lense Adapter System for the
MammoView ® Product Line.
As the first six months of 2010 drew to a close, the Company
appointed Fred Schiemann as CFO and Director to provide financial
leadership amidst growth. Mr. Schiemann brings a strong
administrative background in the small-cap company sector as well
as expertise in taxation, auditing and public securities work. As a
result, later in 2010, Solos followed by announcing that the
Company’s management had approved its 2011 recapitalization plan in
order to position itself for growth over the next twelve months.
The recapitalization plan allows Solos greater flexibility to
utilize the assets of the Company in the future for
corporate purposes; including raising capital, acquisitions or
employee compensation, with